We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+27.77%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$8.73B
AUM Growth
+$1.49B
Cap. Flow
+$225M
Cap. Flow %
2.57%
Top 10 Hldgs %
31.85%
Holding
234
New
17
Increased
80
Reduced
68
Closed
12

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$143M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$63.9M
3
MRSN
Mersana Therapeutics
MRSN
+$42.8M
4
DXCM icon
DexCom
DXCM
+$32.7M
5
ABBV icon
AbbVie
ABBV
+$32.5M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$154M
2
HALO icon
Halozyme
HALO
+$51.2M
3
CRL icon
Charles River Laboratories
CRL
+$49.6M
4
CDNA icon
CareDx
CDNA
+$44.7M
5
MDT icon
Medtronic
MDT
+$40.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.9%
2 Technology 0.6%
3 Industrials 0.33%
4 Financials 0.11%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BF.B icon
201
Brown-Forman Class B
BF.B
$12B
$445K 0.01%
5,600
-2,000
-26% -$154K
BKNG icon
202
Booking.com
BKNG
$138B
$445K 0.01%
5,000
– –
TCOM icon
203
Trip.com Group
TCOM
$27.5B
$442K 0.01%
13,100
– –
AXP icon
204
American Express
AXP
$223B
$435K 0.01%
3,600
– –
MCO icon
205
Moody's
MCO
$81.7B
$435K 0.01%
1,500
-500
-25% -$140K
FDS icon
206
Factset
FDS
$9.05B
$432K ﹤0.01%
1,300
-400
-24% -$132K
FTNT icon
207
Fortinet
FTNT
$112B
$431K ﹤0.01%
14,500
– –
SWKS icon
208
Skyworks Solutions
SWKS
$9.06B
$428K ﹤0.01%
2,800
-900
-24% -$132K
TW icon
209
Tradeweb Markets
TW
$21.3B
$425K ﹤0.01%
6,800
– –
MCK icon
210
McKesson
MCK
$98.5B
$423K ﹤0.01%
2,430
-1,462
-38% -$243K
MKC icon
211
McCormick & Company Non-Voting
MKC
$13.4B
$421K ﹤0.01%
4,400
-1,200
-21% -$113K
SCI icon
212
Service Corp International
SCI
$11.4B
$417K ﹤0.01%
8,500
– –
MKL icon
213
Markel Group
MKL
$25B
$413K ﹤0.01%
400
– –
WSO icon
214
Watsco Inc
WSO
$14.9B
$408K ﹤0.01%
1,800
-1,000
-36% -$230K
CLX icon
215
Clorox
CLX
$11.6B
$404K ﹤0.01%
2,000
– –
SPGI icon
216
S&P Global
SPGI
$126B
$394K ﹤0.01%
1,200
-500
-29% -$169K
AZPN
217
DELISTED
ASPEN TECHNOLOGY INC
AZPN
$391K ﹤0.01%
3,000
– –
DPZ icon
218
Domino's
DPZ
$11B
$383K ﹤0.01%
1,000
– –
BLKB icon
219
Blackbaud
BLKB
$1.5B
$236K ﹤0.01%
4,107
– –
ICPT
220
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$198K ﹤0.01%
8,000
-696,976
-99% -$23.1M
VTRS icon
221
Viatris
VTRS
$20.1B
$172K ﹤0.01%
+9,169
New +$150K
CVET
222
DELISTED
Covetrus, Inc. Common Stock
CVET
$44K ﹤0.01%
1,520
– –
ADBE icon
223
Adobe
ADBE
$89.5B
– –
-1,100
Closed -$539K
HTHT icon
224
Huazhu Hotels Group
HTHT
$12.4B
– –
-13,500
Closed -$584K
IART icon
225
Integra LifeSciences
IART
$1.54B
– –
-122,426
Closed -$5.78M
6 7 8
9
10

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q4 2020 Portfolio in Review

As of Q4 2020, Bellevue Group held 234 positions worth $8.73B, up 21% from $7.24B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Bellevue Group's Q4 2020 filing shows 17 new, 80 increased, 68 reduced and 12 closed positions. Its largest new stake was Mersana Therapeutics: 77,040 shares worth $51.3M. The largest sale was MyoKardia, Inc. Common Stock, an estimated $154M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Technology and Industrials.

  • Bellevue Group's largest Q4 2020 buy was Mersana Therapeutics: 77,040 shares worth $51.3M.
  • Bellevue Group added most to Biogen in Q4 2020, an estimated $143M increase.
  • Bellevue Group's biggest Q4 2020 reduction was Halozyme, cutting an estimated $51.2M.
  • Bellevue Group fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $154M.
  • Bellevue Group's ten largest holdings make up 32% of its $8.73B portfolio in Q4 2020.
  • Bellevue Group opened 17 new positions and closed 12 in Q4 2020.
  • Bellevue Group's portfolio value rose 21% quarter-over-quarter to $8.73B.

Based on Bellevue Group's 13F filing for Q4 2020, filed 16 Feb 2021.